At a glance

What is TB-500?

TB-500 is a synthetic peptide sold for recovery and injury repair, commonly described as the actin-binding fragment of the natural protein thymosin beta-4 (a short piece of that larger molecule, not the full 43-amino acid protein). An important caveat is that gray-market labeling is inconsistent: material sold as "TB-500" sometimes contains the full-length protein or other fragments. It is not an approved medicine.

How does it work?

TB-500 is assumed to share the actions of full-length thymosin beta-4, namely:

• Binding the cell-structure protein actin
• Promoting cell migration
• Promoting blood-vessel formation
• Promoting reduced inflammation

A review of the full-length protein's regenerative biology¹ adds the mobilization of stem and progenitor cells and less scarring, across skin, eye, heart, and brain repair models. Importantly, this is largely extrapolated from the full-length protein's animal data; the fragment itself has far less dedicated study. This describes a proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. TB-500 is not approved by the FDA. As neutral regulatory facts: On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend TB-500² (free base and acetate) for the 503A compounding list, citing wound healing. But, because that vote is only a recommendation and FDA adoption is pending, TB-500 is not currently on the list and cannot be legally compounded on that basis. The same coverage of the meeting lists TB-500 among the peptides voted on and does not list full-length thymosin beta-4. In sport, it is treated as thymosin beta-4 and is prohibited at all times under the WADA list.

What does the research show?

There is essentially no human evidence for the fragment. There are no completed human efficacy trials of the TB-500 fragment, and human safety data specific to it are not published. The only clinical data belong to the full-length protein, thymosin beta-4, which has been tested only in small, early trials, such as a randomized dose-escalation venous-ulcer study³ designed to assess safety and tolerability, and a Phase III eye-drop trial in neurotrophic keratopathy⁴. Those results do not directly transfer to the fragment. So the marketed recovery benefit is unproven in people.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a synthetic fragment (Ac-LKKTETQ) covering the actin-binding domain of thymosin beta-4, which is a full 43-amino acid native protein. The two molecules have different chemical identities and different regulatory histories. The clinical trial data that exists for corneal wound healing and venous ulcers was generated using full-length thymosin beta-4, not the TB-500 fragment. The fragment in TB-500 was identified and characterized⁶ in Drug Testing and Analysis in 2012.

Is TB-500 FDA-approved?

No. As of September 2026, TB-500 is not FDA-approved for any indication. FDA has removed it from Category 2⁷ after the nomination was withdrawn, but it is not on the 503A bulks list or in Category 1, so licensed 503A pharmacies in the United States cannot compound it.

Is TB-500 legal in the United States?

TB-500 cannot legally be obtained through a licensed compounding pharmacy in the United States. Products marketed as TB-500 for human use exist in unregulated channels outside pharmaceutical oversight. For athletes, it is also prohibited at all times under the 2026 WADA Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics).

Can a doctor prescribe TB-500?

No. TB-500 is not on the 503A bulks list or in Category 1, which means licensed compounding pharmacies cannot legally include it in compounded preparations. FDA removed it from Category 2 in April 2026 after the nomination was withdrawn, and that removal did not make it eligible. There is no legal pathway for a physician to prescribe TB-500 in the United States through a licensed pharmacy. Any TB-500 being administered to patients outside a formal clinical trial falls outside the regulated pharmaceutical framework.

What is the difference between TB-500 and BPC-157?

TB-500 and BPC-157 are distinct synthetic peptides with different amino acid sequences, different proposed mechanisms, and different origins. TB-500 is derived from the actin-binding domain of the native protein thymosin beta-4. BPC-157 is derived from a human gastric juice protein. As of September 2026, FDA lists both as nominated but withdrawn, neither is on the 503A bulks list, both are on the WADA Prohibited List, and neither has completed human efficacy trials for musculoskeletal applications. There are no FDA-approved or clinically validated protocols for combining them.

Does TB-500 show up on a drug test?

Yes. TB-500 and thymosin beta-4 fragments are detectable in biological samples. Detection methods for TB-500⁸ in equine urine and plasma were published in the Journal of Chromatography A in 2012, and a 2024 equine population study⁹ in Drug Testing and Analysis described a strategy for detecting thymosin beta-4 misuse in racehorses. A doping control laboratory has also proposed a detection method⁶ for the TB-500 fragment in plasma and urine.

Are there any human studies on TB-500?

No completed, peer-reviewed human efficacy trials for TB-500 (the synthetic fragment) have been published as of September 2026, and FDA has identified no human exposure data⁷ for it. Human clinical trial data exists for full-length thymosin beta-4 in ophthalmic indications, including a Phase 3 RCT in neurotrophic keratopathy⁴ reported in 2022 in the International Journal of Molecular Sciences (N = 18; primary 4-week healing endpoint 60% vs 12.5%, p = 0.0656). That data applies to the full-length molecule administered topically to the eye, not to systemically administered TB-500.

Are peptides legal again after 2026?

The regulatory landscape for peptides has evolved through multiple FDA rulemaking cycles. As of September 2026, TB-500 is not on the 503A bulks list or in Category 1. FDA removed it from Category 2⁷ in April 2026 after the nomination was withdrawn. On July 23, 2026, an FDA advisory committee voted 8-6 to recommend TB-500¹⁰ for the bulks list for wound healing, a non-binding vote that FDA must follow with rulemaking. Some other peptides have different classification statuses depending on their individual regulatory histories. For authoritative current information, consult the FDA's published bulk drug substances list⁷.

More for bones & muscles